Learn
Looking for more information?
Contact our responsive and friendly client services team any time.
Current price
$0.06
▾0.002 (3.45%)
Last trade: 28/03, 12:16PM
Market cap
$6.83m
Market closed
Talk to Island Pharmaceuticals Limited directly.
Sign up to their Investor Hub for direct access to the Island Pharmaceuticals Limited team, ask them questions, and see personal updates.
Investor Presentations
Principal Activity
Island Pharmaceuticals is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. Their main asset – ISLA-101 - was initially developed by their wholly owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Island has repurposed ISLA-101, an antiviral oral drug to treat mosquito-borne viruses (eg dengue fever / Zika) and intends to complete Phase II studies with a significantly de-risked clinical program.
News
Announcements
Filter
Announcement | T+2 Movement | Date |
---|---|---|
Market Data
Day
3m
1yr
5yr
Current price
$0.06
Open price
-
Day low-high
-
Price change
Percent change
Previous close
-
Volume
-
Turnover
-
Bid price
-
Ask price
-
Market cap
-
Shares outstanding
-
Year high
-
Year low
-
Year low-high
-
Earnings per share
-
Price/earnings ratio
-
Dividend yield
-
Dividend per share
-
Franking
-
Investor Presentations
News
Sector Peers
Company | Market Cap | ||
---|---|---|---|
Support
Live Chat
Markets